Mangoceuticals Inc (MGRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$0.41+5.30%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · MGRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Complete business combination with Nuclea Energy and advance development and commercialization of the Morpheus microreactor technology.
Stated in 2 recent disclosures in 2026-Q3 timeframe. The company is pursuing a business combination with Nuclea Energy to commercialize the Morpheus microreactor, which remains in the conceptual design stage. No revenue or income impact from this initiative is yet reported, so progress is at the strategic announcement stage with limited financial delivery so far.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Regain compliance with Nasdaq minimum bid price requirement and obtain necessary stockholder and Nasdaq approvals for business combination.
Stated in 2 disclosures in 2026-Q3. The company received a Nasdaq extension until February 1, 2027, to regain compliance with the minimum bid price rule. No financial improvement in share price or market cap is reported here, so the priority is ongoing with limited substantive delivery to date.
Focus on improving operating income and reducing net losses through operational improvements and cost management.
Stated as a priority in 8 consecutive quarters from 2024-Q3 through 2026-Q2. Operating income improved significantly from a loss of $7.54M in 2025-Q3 to a loss of $1.03M in 2026-Q2, and net loss improved from $7.62M to $1.31M over the same period. This shows delivering progress on financial performance improvement.
“Operating income was negative $1,033,040 with net loss of $1,312,653.”
“Operating income was negative $3,126,326 with net loss of $3,403,150.”
“Operating income was negative $644,554 with net loss of $2,769,567.”
“Operating income was negative $7,542,926 with net loss of $7,618,218.”
“Operating income was negative $5,268,495 with net loss of $5,415,818.”
“Operating income was negative $4,576,374 with net loss of $4,839,391.”
“Operating income was negative $1,677,661 with net loss of $1,948,352.”
“Operating income was negative $1,758,074 with net loss of $1,999,233.”
Management expects testosterone replacement therapy (TRT) to be the main growth driver for the company going forward.
Newly stated in early 2026. Management identified TRT as the primary growth driver. Financials show flat revenue around $67.8M to $68.8M in early 2026 quarters, indicating limited revenue growth so far from this focus.
The company received a deficiency notification from Nasdaq for not meeting the $1.00 per share bid price requirement.
Over the trailing year it converted 0.48x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
58 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.